The MARIO-8 study is part of Infinity's broader development program for eganelisib, which includes ongoing studies in other indications such as triple-negative breast cancer and non-small cell lung cancer. The company is committed to exploring the full potential of eganelisib across a range of tumor types and treatment settings.
Eganelisib is a first-in-class, oral immuno-oncology drug that selectively inhibits phosphoinositide-3 kinase-gamma (PI3K-gamma). By targeting this specific pathway, eganelisib has the potential to enhance anti-tumor immune responses and overcome resistance to checkpoint inhibitors like pembrolizumab.
Infinity Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. With a strong pipeline and strategic partnerships, Infinity is well-positioned to make significant contributions to the field of oncology.